Investments
13Portfolio Exits
2Funds
1
Want to inform investors similar to Cobro Ventures about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Cobro Ventures News
Nov 7, 2022
November 7, 2022 The round was led by Cobro Ventures and Lightchain Capital. The company intends to use the funds to expand operations and its business reach. Led by CEO Drew Dennison and founder, President, and CSO Dr. Chris Bahl, AI Proteins is using its de novo protein design platform to unlock the therapeutic potential of miniproteins, which are peptides that form a hyperstable three-dimensional structure. Miniproteins can solve many issues facing traditional antibody development, acting to drive down costs, speed up therapeutic development, and improve success rates.
Cobro Ventures Investments
13 Investments
Cobro Ventures has made 13 investments. Their latest investment was in Angiocrine Bioscience as part of their Series B on March 3, 2022.
Cobro Ventures Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
3/29/2022 | Series B | Angiocrine Bioscience | Yes | Cobro Ventures, and Undisclosed Investors | 1 | |
2/9/2022 | Series B | Regenacy Pharmaceuticals | $9.3M | No | 3E Bioventures, Cobro Ventures, Taiwania Capital, Undisclosed Investors, and Yonjin Venture | 2 |
1/27/2022 | Series A | NextRNA Therapeutics | $46.8M | Yes | 2 | |
1/25/2022 | Series B - II | |||||
1/21/2022 | Seed VC |
Date | 3/29/2022 | 2/9/2022 | 1/27/2022 | 1/25/2022 | 1/21/2022 |
|---|---|---|---|---|---|
Round | Series B | Series B | Series A | Series B - II | Seed VC |
Company | Angiocrine Bioscience | Regenacy Pharmaceuticals | NextRNA Therapeutics | ||
Amount | $9.3M | $46.8M | |||
New? | Yes | No | Yes | ||
Co-Investors | Cobro Ventures, and Undisclosed Investors | 3E Bioventures, Cobro Ventures, Taiwania Capital, Undisclosed Investors, and Yonjin Venture | |||
Sources | 1 | 2 | 2 |
Cobro Ventures Portfolio Exits
2 Portfolio Exits
Cobro Ventures has 2 portfolio exits. Their latest portfolio exit was C4 Therapeutics on October 02, 2020.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
10/2/2020 | IPO | Public | 2 | ||
Date | 10/2/2020 | |
|---|---|---|
Exit | IPO | |
Companies | ||
Valuation | ||
Acquirer | Public | |
Sources | 2 |
Cobro Ventures Fund History
1 Fund History
Cobro Ventures has 1 fund, including Cobro Ventures Opportunity Fund.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
Cobro Ventures Opportunity Fund | 1 |
Closing Date | |
|---|---|
Fund | Cobro Ventures Opportunity Fund |
Fund Type | |
Status | |
Amount | |
Sources | 1 |
Cobro Ventures Team
6 Team Members
Cobro Ventures has 6 team members, including current Founder, Chief Executive Officer, Marc A. Cohen.
Name | Work History | Title | Status |
|---|---|---|---|
Marc A. Cohen | Founder, Chief Executive Officer | Current | |
Name | Marc A. Cohen | ||||
|---|---|---|---|---|---|
Work History | |||||
Title | Founder, Chief Executive Officer | ||||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.